Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Woman throwing punch at punching bag.

Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics

(As of December 31, 2023)

  • $167M

    FY’23 Revenue

    7% YtY growth

  • $25-30M

    Adj. EBITDA expected in 2024

    >75%

    Adj. EBITDA
    growth YtY

  • $73M

    Cash balance

    with no debt

  • #1

    OA Pain
    U.S. Market Share

    ~25M

    Injections
    Worldwide

Recent News
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 11, 2024

BEDFORD, Mass., July 11, 2024 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on July 1, 2024, Anika...

Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs
Jul 11, 2024

Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika’s proprietary hyaluronic acid (HA) regenerative portfolio Over 300 surgeries...

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 7, 2024

BEDFORD, Mass., June 7, 2024 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on June 3, 2024, Anika...

All Press Releases

2024 Annual Meeting Materials
Featured Event
Q1 2024 Anika Therapeutics Earnings Conference Call
Wednesday, May 8, 2024
5:30pm EDT

See All Events

Current Investor Presentation

View PresentationView More
Investor Contacts

Primary IR Contact

  • Mark Namaroff

    Vice President, Investor Relations, ESG, and Corporate Communications

    Anika Therapeutics, Inc.

    Phone: (781) 457-9287

    Email: investorrelations@anika.com

  • Transfer Agent

    Equiniti Trust Company LLC

    6201 15th Avenue

    Brooklyn NY 11219

    Phone: (800) 967-5449

Want Alerts? Sign up for alerts and never miss an Investor update!

Subscribe

To Top